Home |  Contact Us | Site Map

Investor Relations

Corporate Profile

Welcome! Whether you are a potential investor in BioCryst Pharmaceuticals or you are already a shareholder, our investor center is the primary source of information about the company. Just choose a topic, or if you have a question, e-mail us.

$8.82 - 0.93
Oct 9, 2015 at 3:45 PM ET
Intraday data provided by eSignal

Recent Releases View All Releases

BioCryst Announces Completion of Patient Enrollment in OPuS-2: a Clinical Trial of Avoralstat in Patients With HAE
RESEARCH TRIANGLE PARK, N.C., Oct. 8, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) today announced that it has completed enr...

Read More

BioCryst Announces Successful Phase 1 Clinical Trial of BCX7353
Advancing once-daily BCX7353 into a Phase 2 trial in hereditary angioedema patients RESEARCH TRIANGLE PARK, N.C., Oct. 8, 2015 (GLOBE NEWS...

Read More

Investor Relations

Rob Bennett, Vice President Investor Relations & Operations

Proxy Online

For more information click here.

Stockholder Services

Questions about stock transfers and lost certificates should be directed to the transfer agent:
American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
1-800-937-5449 (toll free in US and Canada)
1-718-921-8200 (callers outside the US and Canada)